论文部分内容阅读
目的 为观察t-PA(组织型纤溶酶原激活剂 )在相同浓度下 ,结膜下注射与前房内注射对眼内纤维蛋白渗出的治疗效果。方法 t-PA治疗浓度为 5 0 μg/ml,每次注射量两种方法均为 0 3ml,一次注射不能使纤维蛋白渗出完全溶解者间隔 2 4～ 4 8h重复给药 ,直至吸收。结果 前房内注射 :眼内纤维蛋白在一次注射t-PA后完全溶解者所需时间为 0 5～ 3h ,平均 1h。结膜下注射 :眼内纤维蛋白渗出完全吸收时间为注药后 1～ 15天 ,平均 5～ 8天。二者相比有显著差异 (P <0 0 1)。结论 t -PA治疗无明显并发症 ,全部病人随访 1～ 2个月未见眼内纤维蛋白渗出复发 ,认为t-PA具有显著的抑制纤维蛋白渗出及眼内纤维膜形成的作用 ,前房内注射较结膜下注射效果明显
Objective To observe the therapeutic effect of t-PA (tissue-type plasminogen activator) on the intraocular fibrin exudation at the same concentration of subconjunctival injection and anterior chamber injection. Method t-PA treatment concentration of 50μg / ml, each injection volume of both methods were 0 3ml, an injection can not make fibrin exudation completely dissolved interval 24 ~ 48h repeated administration until absorption. Results of anterior chamber injection: intraocular fibrin in a single injection of t-PA completely dissolved after the time required for 0 5 ~ 3h, an average of 1h. Subconjunctival injection: Intraocular fibrin exudation complete absorption time 1 to 15 days after injection, an average of 5 to 8 days. There was a significant difference between the two groups (P <0.01). Conclusion There is no obvious complication of t-PA treatment. All the patients have no recurrence of intraocular fibrin exudation within one to two months of follow-up. It is concluded that t-PA has a significant inhibitory effect on fibrin exudation and intraocular fibrosis. Room injection than conjunctival injection effect is obvious